Explore more publications!

Sci-Tech North Carolina: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Sci-Tech North Carolina.

Press releases published on January 13, 2026

Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy
AIQ introduces direct-to-menu media, closing the gap between cannabis advertising and purchase
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones
Voting Rights and Shares Capital of the Company
Information mensuelle relative au nombre total de droits de vote  et d’actions composant le capital social
Mercury Systems to Report Second Quarter Fiscal Year 2026 Financial Results on February 3, 2026
INVO Fertility to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026
Crane NXT Announces Dates for Fourth Quarter and Full Year 2025 Earnings Release and Earnings Call
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
AlphaTON Capital Corp Announces $15 Million Registered Direct Offering
$PIKZ Goes Live: AI-Driven Sports Intelligence Launches on MEXC & Uniswap Following Successful 148 ETH Presale
Streetline Launches First-of-Its-Kind Public-Private Partnership Smart Truck Parking Deployments for States Nationwide
Deck Adds Former Arizona Cardinals WR Larry Fitzgerald Jr. as Investor; Launches "Impossible Integrations" Campaign
Syncfusion® Announces Essential Studio® 2025 Volume 4
Metabo Drops Examined: Is It Legit for Weight Loss? Safety Checks and Consumer Analysis 2026
Belle AI LTD Welcomes Raviv Cohen as Co-Founder to Enhance Retail Network and Forecasting Capabilities
Cyclr launches new innovation in the AI connectivity space - MCP PaaS
La FDA américaine accorde la désignation  « Breakthrough Therapy » à l’IPN60340 (ICT01) d’Ipsen dans la leucémie myéloïde aiguë de première ligne chez les patients inéligibles à une chimiothérapie intensive
U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions